Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Teva, Celltrion Partner | Technology Networks
Teva, Celltrion win FDA approval for Rituxan biosimilar - Globes
Jobs with Celltrion Healthcare (Formerly Known As Celltrion) | page 2
Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Amgen and Allergan's Kanjinti (trastuzumab-anns) Biosimilar Product Profile
Celltrion/Teva's Herceptin biosimilar approved in US -
Celltrion riding high on biosimilars - Nikkei Asia
Teva confident in September approval for migraine drug despite latest Celltrion plant citation | Fierce Pharma
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Teva bolsters its biosimilar business through $160m Celltrion deal
Celltrion signs $160m drug license deal with Teva for North America - Nikkei Asia
Celltrion And Teva Catch Up On Canadian Trastuzumab :: Generics Bulletin
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
New data raise profile of Truxima at EHA 2021
Celltrion says COVID-19 antibody kills virus within 5 days; shares surge - KED Global
JUNG, Ji-Ho on Twitter: "#Ajovy approved by FDA. #teva sells #Celltrion will make it in Korea. https://t.co/tKTp91jDXs" / Twitter
Teva teams with Celltrion in $160m biosimilar deal - Globes
